trial · primary record
Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
Multiple Myeloma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 70 |
| Primary completion | 2032-11 |
| Primary endpoint | Establish Maximum Tolerated Dose (MTD) |
| Registry ID | NCT04822337 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:36.356Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04822337
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.